H.C. Wainwright analyst Mike Colonnese says the recent selloff in the bitcoin miners “has created a very attractive buying ...

H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended ...

H.C. Wainwright lowered the firm’s price target on Annexon (ANNX) to $20 from $30 and keeps a Buy rating on the shares. The positive SAD/MAD ...

H.C. Wainwright lowered the firm’s price target on Neumora Therapeutics (NMRA) to $18 from $30 and keeps a Buy rating on the shares. The firm ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell ...

We recently compiled a list of the 10 Trending AI Stocks That Analysts Are Monitoring. In this article, we are going to take a look at where BlackSky Technology Inc. (NYSE:BKSY) stands against the ...

Following today's pullback, Geron is now down roughly 17% over the last year. With sales momentum for the company's lead treatment weakening, the company's development pipeline has taken on added ...

Revenue for the full year 2024 grew 69% year-over-year to $162.4 million. Net income was $331.4 million, with adjusted EBITDA reaching $555.7 million. Both figures were influenced by a $509.3 million ...

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies ...

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com. IN8bio is a clinical-stage ...